Literature DB >> 26586773

IL17A-Mediated Endothelial Breach Promotes Metastasis Formation.

Paulina Kulig1, Sara Burkhard1, Joanna Mikita-Geoffroy1, Andrew L Croxford1, Nadine Hövelmeyer2, Gabor Gyülvészi1, Christian Gorzelanny3, Ari Waisman2, Lubor Borsig4, Burkhard Becher5.   

Abstract

The role of the IL23/IL17A axis in tumor-immune interactions is a matter of controversy. Although some suggest that IL17A-producing T cells (TH17) can suppress tumor growth, others report that IL17A and IL23 accelerate tumor growth. Here, we systematically assessed the impact of IL17A-secreting lymphocytes in several murine models of tumor lung metastasis. Genetic fate mapping revealed that IL17A was secreted within lung metastases predominantly by γδ T cells, whereas TH17 cells were virtually absent. Using different tumor models, we found Il17a(-/-) mice to consistently develop fewer pulmonary tumor colonies. IL17A specifically increased blood vessel permeability and the expression of E-selectin and VCAM-1 by lung endothelial cells in vivo. In transgenic mice, specific targeting of IL17A to the endothelium increased the number of tumor foci. Moreover, the direct impact of IL17A on lung endothelial cells resulted in impaired endothelial barrier integrity, showing that IL17A promotes the formation of lung metastases through tumor-endothelial transmigration. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26586773     DOI: 10.1158/2326-6066.CIR-15-0154

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  18 in total

Review 1.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

2.  The dichotomy of T helper 17 cells in cancer.

Authors:  Lekh N Dahal
Journal:  Nat Rev Immunol       Date:  2017-08-21       Impact factor: 53.106

3.  Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis.

Authors:  Daniel Octavian Costache; Oana Feroiu; Adelina Ghilencea; Mihaela Georgescu; Ana Căruntu; Constantin Căruntu; Sorin George Țiplica; Mariana Jinga; Raluca Simona Costache
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

Review 4.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Authors:  Bruno Silva-Santos; Sofia Mensurado; Seth B Coffelt
Journal:  Nat Rev Cancer       Date:  2019-07       Impact factor: 60.716

5.  Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A.

Authors:  Yuming Kang; Guoai Su; Jianmin Sun; Yanli Zhang
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

Review 6.  The Interplay Between Innate Lymphoid Cells and the Tumor Microenvironment.

Authors:  Laura Ducimetière; Marijne Vermeer; Sonia Tugues
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

7.  Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.

Authors:  Zhixing Kuang; Xun Li; Rongqiang Liu; Shaoxing Chen; Jiannan Tu
Journal:  Front Cell Dev Biol       Date:  2021-05-17

8.  Th17 Cells in Protection from Tumor or Promotion of Tumor Progression.

Authors:  M Rita I Young
Journal:  J Clin Cell Immunol       Date:  2016-06-20

9.  Comprehensive genomic and prognostic analysis of the IL‑17 family genes in lung cancer.

Authors:  Tingting Liao; Jinshuo Fan; Zhilei Lv; Juanjuan Xu; Feng Wu; Guanghai Yang; Qi Huang; Mengfei Guo; Guorong Hu; Mei Zhou; Limin Duan; Sufei Wang; Yang Jin
Journal:  Mol Med Rep       Date:  2019-04-15       Impact factor: 2.952

10.  Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy.

Authors:  Monika Bilska; Anna Pawłowska; Ewelina Zakrzewska; Agata Chudzik; Dorota Suszczyk; Marek Gogacz; Iwona Wertel
Journal:  J Oncol       Date:  2020-02-21       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.